• Plenary
  • Workshop
  • Side Meeting
  • 08:00

    Registrations and refreshments

    Time: 08:00

  • 09:30

    Opening session and Partner introductions

    Time: 09:30

    Plenary

    The official opening ceremony from the Partners, hosts and officials of the World Hepatitis Summit 2017. This session will outline the expected contributions from civil society, government and WHO Member States in advancing the viral hepatitis agenda.

    Welcome and introductions:

    • World Hepatitis Alliance.

    • World Health Organization.

    • Brazilian delegation.

    • UNITAID.

    • NOhep Visionaries.

  • 11:00

    Break

    Time: 11:00

  • 11:30

    Making elimination a reality

    Time: 11:30

    Plenary

    This opening plenary session looks at the opportunities and challenges that lie ahead in the global implementation of viral hepatitis plans.

    Worldwide, approximately 257 million people have chronic hepatitis B infection and 71 million people have chronic hepatitis C infection - two liver infections that together result in an estimated 1.34 million deaths worldwide. A stepped-up global response can no longer be delayed.

    This session will bring together a group of visionaries from all walks of life who champion the cause of elimination to participate in a dialogue around achieving the common goal of elimination.

  • 13:00

    Lunch

    Time: 13:00

  • 14:00

    Strategic direction 1: strategic information for focused action

    Time: 14:00

    Plenary

    Session Lead: Sharon Hutchinson

    The Summit’s agenda takes the Global Health Sector Strategy on Viral Hepatitis (GHSS) - and its 5 strategic directions - as its framework. In this plenary session, strategic direction 1 looks at advocacy, political commitment and national planning.

    Presentations:

    • Global viral hepatitis situation and response.
      Dr. Marc Bulterys, World Health Organization
    • WHO country profile report.
    • Shanley Smith, Glasgow Caledonian University
    • Progress in integrating civil society in the global viral hepatitis response.
      Raquel Peck, World Hepatitis Alliance
    • Country examples demonstrating the role of strategic information in national planning.

    Session objectives:

    To highlight

    • The role and importance of strategic information in planning and monitoring national responses.
    • The priority actions for countries and role of WHO in supporting countries.
    • The latest data on the global viral hepatitis situation and response.
    • Progress made in integrating civil society in the global viral hepatitis response and on global awareness activities.
    • Country examples demonstrating the important role of strategic information for focused action.
  • 15:30

    The critical role of strategic information : HCV elimination in Georgia

    Time: 15:30

    Parallel workshop

    Session Lead: Francisco Averhoff

    Chair: Dr. Francisco Averhoff, Centers for Disease Control and Prevention

    Chair: Dr. Helen Harris, Public Health England

    Presentations:

    • Assessing the burden of disease: the planning, conduct and use of a National Seroprevalence Survey.
    • Dr. Amiran Gamkrelidze, National Center for Disease Control and Public Health of Georgia
    • Monitoring the care cascade: developing a robust screening and treatment information system.
    • Dr. Lia Gvinjilia, CDC Foundation for US Centers for Disease Control and Prevention
    • The role of research and project monitoring in HCV elimination.
    • Dr. Tinatin Kuchuloria, CDC Foundation for US Centers for Disease Control and Prevention
    • Modelling the epidemic to guide interventions.
    • Project oversight and guidance: the role of an independent Technical Advisory Group (TAG).
    • Dr. Muazzam Nasrullah, U.S. Centers for Disease Control and Prevention

    Session objectives:

    • Learn the importance of a well conducted population serosurvey to guide development of an evidence-based national strategy/plan.
    • Understand the importance of a robust strategic information system to guide and monitor an elimination program.
    • Learn the key role of partnerships in developing a world class information system.
  • 15:30

    How to develop a national plan on viral hepatitis?

    Time: 15:30

    Parallel workshop

    Session Lead: Hande Harmanci

    Presentations:

    • Developing a national plan: introduction.
      Dr. Hande Harmanci, World Health Organization
    • The importance of national planning.
    • Identifying the best processes to create national plans.
    • Critically appraise a sample national hepatitis plan using a checklist.

    Session objectives:

    • Learn to differentiate between national strategies and plans.
    • Identify the best processes to create national plans.
    • Use a checklist to align national plans with the Global Health Sector Strategy on Viral Hepatitis.
    • Critically appraise a national plan for comprehensiveness.
  • 15:30

    How to develop an investment case?

    Time: 15:30

    Parallel workshop

    Session Lead: Yvan Hutin

    Presentations:

    • An investment case: The why and the proposed WHO approach.
      Dr. Yvan Hutin, World Health Organization
    • Indian case study: Need for an investment case.
    • Dr. Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences and Dr. Jagpreet Chhatwal, Harvard Medical School and Massachusetts General Hospital
    • Breakout interactive session.
    • Debrief of the solution to the exercise.
    • WHO wrap-up: How economic analysis was used in the case of Egypt.

    Session objectives:

    • Describe the role of an investment case/economic analysis in the national planning process.
    • Differentiate a cost effectiveness analysis from health care perspective from a broader cost-benefit analysis/investment case.
    • Identify the elements needed for a national investment case/economic analysis in practice.
  • 15:30

    How to develop successful awareness raising campaigns? Harnessing the learning from civil society and other global initiatives

    Time: 15:30

    Parallel workshop

    Session Lead: Achim Kautz

    Speakers: Sema Mandal , John Ward

    Chair: Achim Kautz, Leberhilfe Projekt gUG

    Chair: Dr. Sema Mandal, Public Health England

    Presentations:

    • Introduction.
    • Presentation from a communications expert.
    • Dr. Renata Schiavo, ‎Strategic Communication Resources, and Health Equity Initiative, and Columbia University
    • Examples, data selection, interaction of NGOs and governments.
    • The US example.
    • Dr. John Ward, US Centers for Disease Control and Prevention
    • Discussion.

    Session objectives:

    • Lessons learnt from global awareness strategies in other fields.
    • Lessons learnt from major hepatitis awareness strategies.
    • Identify key data needed to structure awareness strategies.
    • How a global awareness strategy can be used - based on local data - at a local level?
  • 17:00

    Close of day 1

    Time: 17:00

  • 17:30

    Unitaid’s role in hepatitis C

    Time: 17:30

    Side meeting

    This evening side meeting presents Unitaid’s investment and operating model in the context of the emerging global response to hepatitis C. It will share the results of Unitaid-funded projects related to hepatitis C. It will also explore opportunities for potential future investments. 

    This early morning side meeting will look at

    Presentations:

    • Opening remarks – Unitaid’s model and its relevance for Hepatitis C.
    • Where are we today?
    • Developing a simplified mode of care for HCV.
      Dr Sabrina Sharmin, MSF
    • Creating demand and innovative solutions for access to HCV treatment.
      Khalil Elouardighi, Coalition Plus
    • Facilitating diagnostic solutions.
      Francisco Marinucci, FIND
    • Putting the pieces together to maximise benefits.
      Marc Bulterys, WHO
    • Moderated discussion.
  • 07:30

    End of viral hepatitis? Not without tackling hepatitis E!

    Time: 07:30

    Side meeting

    This early morning side meeting will look at this neglected virus and the limited strategies to control and key challenges/opportunities around it With no no efficacious treatment available for acute fulminant hepatitis E and the limited impact of improvements on safe water and sanitation access in displaced populations, this meeting will examine what can be done to limit the burden worldwide. 

    Presentations:

    • Introduction: Hepatitis E in humanitarian settings.
      Iza Ciglenecki,‎ Médecins Sans Frontières (MSF)
    • Hepatitis E in developing countries: an old disease?
      Dr. Rakesh Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences
    • Hepatitis E in developed countries: a new disease?
      Harry Dalton, Royal Cornwell Hospitals NHS Trust
    • Hepatitis E vaccine: a new control tool?
      Dr. James Shih, Innovax
    • Round table discussion.
      Moderator: Harry Dalton, Royal Cornwell Hospitals NHS Trust
  • 07:30

    Liver societies’ role towards global elimination of hepatitis

    Time: 07:30

    Side meeting

    Presented by AASLD, EASL and ALEH, this early morning side meeting will look at the role of the professional medical societies in the viral hepatitis elimination plan.
  • 08:00

    Registrations and refreshments

    Time: 08:00

  • 09:30

    Strategic direction 2: interventions for impact and strategic direction 3: delivering for equity

    Time: 09:30

    Plenary

    The second day of the Summit is dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity".

    Presentations:

    • Conclusions from the World Hepatitis Summit 2015 and progress made.
      Charles Gore, World Hepatitis Alliance
    • 5 core interventions to reach HBV and HCV elimination.
    • Dr. Yvan Hutin, World Health Organization
    • Access to treatment.
    • Shiba Phurailatpam, APN+
    • Diagnostics: present and future.
    • Dr. Saleem Kamili, US Centers for Disease Control and Prevention
    • Hepatitis C prevention and treatment for vulnerable (or marginalised) populations.
    • Professor Gregory Dore, Kirby Institute, UNSW Sydney and St Vincent’s Hospital, Sydney

    Session objectives:

    • Learn areas of innovation and neglected issues.
    • Hear about the core issues for elimination and equitable access.
    • Gain an overview of the main advocacy areas and gaps.
  • 11:00

    Break

    Time: 11:00

  • 11:30

    Testing interventions

    Time: 11:30

    Parallel workshop

    Session Lead: Francesco Negro

    Presentations:

    • WHO testing guidelines.
    • Professor Philippa Easterbrook, World Health Organization
    • Overview of rapid assays for viral hepatitis agents: what test for what setting?
    • Dr. Saleem Kamili, US Centers for Disease Control and Prevention
    • Are screening campaigns feasible and acceptable: the PROLIFICA experience.
    • The national strategic plan in Georgia.
    • Dr. Amiran Gamkrelidze, National Center for Disease Control and Public Health of Georgia

    Session objectives:

    • Review the scientific, logistical, ethical and political process leading to the implementation of state-of-the-art testing for viral hepatitis.
    • Discuss the feasibility and validity of diagnostic algorithm simplifications.
    • Define what testing strategies should be applied in different settings.
    • Discuss the preliminary results of testing strategies in selected areas.
  • 11:30

    Treatment interventions

    Time: 11:30

    Parallel workshop

    Session Lead: Saeed Sadiq Hamid

    Presentations:

    • The impact of generics in scaling up treatment.
    • Treatment in the private vs public sector.
    • Giten Khwairakpam, amfAR TREAT Asia
    • What price for what drug: is there a science to it?
    • Dr. Andrew Hill, Liverpool University
    • Decentralization and ECHO.

    Session objectives:

    • Highlight the impact various factors have had in significantly up scaling treatment, particularly in the LMIC.
    • Identify what treatment intervention strategy would work best in their own environments.
  • 11:30

    Prevention interventions

    Time: 11:30

    Parallel workshop

    Session Lead: Niklas Luhmann

    Presentations:

    • WHO injection safety project.
    • Dr. Arshad Altaf, World Health Organization
    • Mother to child/vertical transmission and birth dose vaccination.
    • HCV prevention among people who use drugs: evidence and ways forward.
      Dr. Niklas Luhmann, Médecins du Monde
    • Blood safety.

    Session objectives:

    • Discuss different core areas of viral hepatitis prevention.
    • Hear country examples of good practice for health facility injection safety, vertical transmission and blood product safety.
  • 11:30

    Delivering equitable services

    Time: 11:30

    Parallel workshop

    Session Lead: Chris Cunningham

    Presentations:

    • Introduction.
    • Distribution of work booklet presenting an equity lens.
      - Individuals and small groups scoring comparative scenarios against an equity standard.
    • Report back.
    • Summary.

    Session objectives:

    • Understand the concept of an "equity lens".
    • Apply an equity framework to policy/service settings relevant to viral hepatitis.
  • 11:30

    Delivering high quality hepatitis services

    Time: 11:30

    Parallel workshop

    Session Lead: Liudmyla Maistat

    Presentations:

    • Australia service delivery model.
    • Professor Margaret Hellard, Burnet Institute, The Alfred Hospital and Monash University
    • HCV testing, treatment and care of people who inject drugs: lessons from Georgia, Kenya and Vietnam.
    • Ukraine case study.
    • HBV diagnostics and indigenous people in Alaska.
    • Dr. Brian McMahon, Alaska Native Tribal Health Consortium

    Session objectives:

    • Review examples of service delivery models for different population groups.
    • Discuss gaps in HBV vaccination, HBV and HCV testing, diagnosis, treatment and care cascade for key populations in different settings and possible solutions to filling in the gaps.
    • Assess the role of case management; peer-to-peer support in community-based or community oriented service delivery.
  • 13:00

    Lunch

    Time: 13:00

  • 14:00

    Parallel workshops

    Time: 14:00

    Parallel workshop

    Parallel workshops from 11.30am repeated. Choose from:

    • Testing interventions
    • Treatment interventions
    • Prevention interventions
    • Delivering equitable services
    • Delivering high quality hepatitis services
  • 15:30

    Access to treatment

    Time: 15:30

    Panel

    Session Lead: Liudmyla Maistat

    This closing panel session examines how to develop the uninterrupted supply of quality-assured vaccines, medicines, diagnostics and other commodities on which effective hepatitis programmes are dependent.

    Chair: Liudmyla Maistat, Medicines Patent Pool

    Chair: Charles Gore, World Hepatitis Alliance

    Presentations:

    • Introduction to Intellectual Property.
    • Ellen ‘t Hoen, University Medical Centre Groningen
    • Patent opposition.
    • Direct price negotiations.
    • Compulsory licensing.
    • Voluntary licensing.
    • Greg Perry, Medicines Patent Pool
    • Open discussion with audience.

    Objectives:

    • To provide an overview of key IP barriers to access hepatitis C treatment.
    • To review different approaches to overcoming price and IP barriers and the progress made.
    • To discuss the possibility for organisations and civil society groups applying different methods and approaches to scaling up access to hepatitis C treatment to be complementary in their strategies.

     

  • 17:00

    Close of day 2

    Time: 17:00

  • 17:30

    Hepatitis in children

    Time: 17:30

    Side meeting

    This evening side meeting looks at hepatitis B and C in children and adolescence. The session will explore some of the recent advances in pediatrics as well as the unique challenges that still need to be overcome within this area.

    Presentations:

    • Hepatitis in children: a global overview.
      Professor Philippa Easterbook, Senior Scientist, World Health Organization
    • Mother to Child Transmission of HBV and HCV.
    • Management of HBV and HCV in children in resource-limited settings.
      Professor Manal El-Sayed, Ain Shams University, Cairo, Egypt
       
  • 17:30

    Addressing the neglected burden of hepatitis D

    Time: 17:30

    Side meeting

    Session Lead: Adele Benzaken

    Speakers: Carlos Varaldo

    This evening side meeting will examine the challenges around the hepatitis D epidemic and what is being done to tackle it. Case studies will include Brazil’s response to the disease in the north of the country as well as highlights from the World Indigenous Peoples Conference on Viral Hepatitis (August 2017, Alaska).

    Presentations:

    Moderator: Carlos Varaldo, NGO Aliança Independente dos Grupos de Apoio, (AIGA).

    • Global context of the hepatitis D treatment.
    • Plan of action of viral hepatitis in the Amazon region.
      Dr Adele Benzaken, Director of Dept. of STIs, HIV/AIDS and Viral Hepatitis
    • Peru’s response to hepatitis D.
      Dr Cezar Cabezas, Viral Hepatitis Specialist, Instituto Nacional de Salud (INS)
    • Highlights from the World Indigenous Peoples Conference.
      Dr Wornei Braga, University of Amazonas

  • 07:30

    Integration and hepatitis service delivery

    Time: 07:30

    Side meeting

    This early morning side meeting will look at developing integrated hepatitis service delivery. It will examine when it is appropriate to integrate; what opportunities exist for integration and the lessons we've learned from HIV and TB.

  • 07:30

    Lancet Commission: accelerating the elimination of viral hepatitis

    Time: 07:30

    Side meeting

    This early morning side meeting will introduce the Lancet Commission for viral hepatitis and its key recommendations in overcoming the barriers to elimination with specific attention paid to the challenges of high burden areas. The meeting will also explore some of the methods used globally as part of different regional and national initiatives.

  • 08:00

    Registrations and refreshments

    Time: 08:00

  • 09:30

    Strategic direction 4: financing for sustainability

    Time: 09:30

    Plenary

    Session Lead: Charles Gore

    The first of two plenary sessions on strategic direction 4, which addresses the sustainable financing of hepatitis responses within a whole health systems approach.

    Presentations:

    • A strategic approach to financing hepatitis.
      Charles Gore, World Hepatitis Alliance
    • Service delivery models.
      Dr. Jeremy Lauer, World Health Organization
    • Financing for hepatitis within a whole health systems approach - a panel discussion.
      Dr. Jeremy Lauer, World Health Organization
      Dr. David Wilson, World Bank
      Dr. Homie Razavi, Center for Disease Analysis

    Session objective:

    • Discover how to approach hepatitis costing, budgeting and financing in a structured way.
    • Understand how the financing system must match the service delivery model and where there are opportunities for integration.
    • Learn how countries can best approach sustainable financing for hepatitis.
  • 11:00

    Break

    Time: 11:00

  • 11:30

    Strategic direction 4: financing for sustainability

    Time: 11:30

    Plenary

    Session Lead: Charles Gore

    This session examines potential hepatitis financing mechanisms that will be required for countries to launch, accelerate and sustain public health responses to viral hepatitis.

    Presentations:

    • The global investment case for viral hepatitis.
    • Engaging Ministries of Finance.
      Eduardo González-Pier, Center for Global Development
    • Public-private sector collaboration.
    • Taryn Barker, Clinton Health Access Initiative
    • Q&A.
    • Country case study panel.

    Session objectives:

    • Understand the global investment case and its use in attracting donors.
    • Learn how to ensure the support of Ministries of Finance.
    • Understand how the public and private sector can be combined.
    • Discover how 3 countries have approached hepatitis financing.

  • 13:00

    Lunch

    Time: 13:00

  • 13:00

    Public private partnership to eliminate hepatitis and the role of the civil society

    Time: 13:00

    Side meeting

    A lunchtime roundtable co-organized by HEP2030 and GPRO

    Achieving the 2030 hepatitis elimination goals will require all stakeholders to work together. The objective of this session is to provide a platform for the participants to discuss their needs and what they can offer. All participants will receive a questionnaire prior to the meeting. We will review the responses according to the following categories: Public health organizations (national and international), donors, philanthropic foundations, industries, civil society, and government entities. We will then use a facilitated discussion (with the audience) to explore the types of partnerships that are needed to achieve the elimination target. This session is recommended for all who want to contribute to helping shape future partnerships. Attendance is by invitation only and all attendees are required to RSVP.

    Presentations:

    Dr Homie Razavi, Managing Director, Center for Disease Analysis.
    Wangsheng Li, President, ZeShan Foundation.

    • Assessing the need for working capital.
    • Help with hard currency: Overcoming the fact Central Asian, Cuba and some of very low income countries do not have access to hard currency.
    • Mutual recognition of product registration to promote competition and lower prices.
    • How can pooled procurement will work in countries with a tendering process in place?
  • 14:00

    Strategic direction 5: innovation for acceleration

    Time: 14:00

    Plenary

    Session Lead: Joseph Tucker

    Innovation can help drive towards the overall objective of hepatitis elimination in a wide range of settings. This innovation session will highlight innovations related to hepatitis B and C products, programs and policies.

    Presentations:

    • Introduction and importance of innovation.
    • Michael Ninburg, World Hepatitis Alliance
    • Innovation plenary.
    • Innovation panel.
    • Dr. Francesco Marinucci, Foundation for Innovative New Diagnostics
      Dr. Joseph Tucker, University of North Carolina
      Dr. Bobby John, Global Health Advocates
      Call for Submissions authors

    Session objectives:

    • Learn the importance of innovation in developing hepatitis B and C control programs, policies and products.
    • Understand new products for hepatitis B and C control that could accelerate detection, treatment and retention.
    • Discuss new policies for expanding access to hepatitis B and C testing, treatment and prevention strategies.
    • Learn about new programs and public health interventions to optimize comprehensive hepatitis care.
  • 15:30

    Summary and handover to WHS19 host country

    Time: 15:30

    A summary of the learning from the World Hepatitis Summit 2017 and a handover to the hosts for 2019.

    Presentations:

    • Event summary and closing thoughts from the Chair.
    • Handover to the World Hepatitis Summit 2019 nation host.
  • 16:15

    Close of the World Hepatitis Summit 2017

    Time: 16:15

Please note this agenda is a draft and subject to change.